Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026

Core Insights - Lifecore Biomedical, Inc. will report its financial results for the fourth quarter and transition period ended December 31, 2025, on March 16, 2026, before market opening [1] - A webcast hosted by Lifecore's senior management team will take place at 8:30 a.m. Eastern Time on the same day to discuss the results [1] Company Overview - Lifecore Biomedical, Inc. is a fully integrated injectables contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across various therapeutic categories [3]